Evidence map›Paper›PMID 41566610›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Microenvironment-Guided Evolution of ssDNA-SWCNT Probes for Selective Recognition of Aggressive Prostate Cancer Phenotypes.

Dakyeon Lee, Seok-Hyeon Lee, Yunseo Jung, Jeongho Lee, Min-Seo Choi, SaeOck Oh, Sungjee Kim, Byoung Soo Kim, Sanghwa Jeong

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dakyeon LeeSchool of Biomedical Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.
Seok-Hyeon LeeSchool of Biomedical Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.
Yunseo JungSchool of Biomedical Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.
Jeongho LeeSchool of Biomedical Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.
Min-Seo ChoiSchool of Biomedical Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.
SaeOck OhDepartment of Anatomy, School of Medicine, Pusan National University, Yangsan, Republic of Korea.
Sungjee KimDepartment of Chemistry, Pohang University of Science and Technology, Pohang, Republic of Korea.ORCID https://orcid.org/0000-0002-1289-1926
Byoung Soo KimSchool of Biomedical Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.
Sanghwa JeongSchool of Biomedical Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.ORCID https://orcid.org/0000-0003-3529-0346

Funding

National Research Foundation of Korea 2022R1A5A2027161National Research Foundation of Korea 2022R1C1C1004803National Research Foundation of Korea RS-2023-00210462
6 · The paper itself

Abstract

Despite advances in prostate cancer detection, distinguishing indolent from aggressive phenotypes remains challenging. We report a microenvironment-guided strategy for evolving phenotype-specific molecular probes using single-stranded DNA-functionalized single-walled carbon nanotubes (ssDNA-SWCNTs). Our approach employs 3D tumor models that recapitulate complex cancer microenvironments, enabling identification of ssDNA sequences with differential binding properties. We developed two distinct probes for prostate cancer cells: PC3D2, which preferentially binds hypoxia-adapted stem-like cells associated with treatment resistance, and PC2D2, which shows enhanced binding to mesenchymal-like cells. These probes exhibit characteristic second near-infrared (NIR-II, 1000-1700 nm) fluorescence, enabling non-invasive detection of aggressive phenotypes in heterogeneous tumors using NIR-II optical imaging. We demonstrate their utility for selective drug delivery to prostate cancer spheroids, resulting in enhanced therapeutic efficacy. This platform represents a significant advancement in precision diagnostics and theranostics, potentially transforming prostate cancer management through phenotype-specific targeting. The methodology offers a generalizable approach for developing nanoprobes that recognize clinically relevant cancer phenotypes based on their unique microenvironmental signatures rather than individual biomarkers.

Indexed as

DNA, Single-StrandedNanotubes, CarbonProstatic NeoplasmsTumor MicroenvironmentCell Line, TumorHumansMaleOptical ImagingPhenotypeDNA, Single-StrandedNanotubes, Carbon3D bioprintingcarbon nanotubeDNAprostate cancerSELEX

Identifiers

PMID41566610
PMCPMC13042387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.